Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

168.74 -1.00 (-0.59%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 7, 2026 Add to My Watchlist

Price and Volume

Volume	401,489
Open	167.73
Bid (Size)	168.60 (2,000)
Ask (Size)	170.75 (100)
Prev. Close	169.74
Today's Range	165.17 - 169.28
52wk Range	86.99 - 191.50
Shares Outstanding	47,190,970
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

April 01, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗

March 25, 2026

The next 10 months might be challenging for this biotech.

Via The Motley Fool

Performance

YTD	-5.6%	-5.6%
1 Month	+2.6%	+2.6%
3 Month	-1.8%	-1.8%
6 Month	+42.2%	+42.2%
1 Year	+71.3%	+71.3%

More News

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗

March 18, 2026

Via The Motley Fool

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q4 2025 Results, Meeting Revenue Forecasts but Posting Wider Loss ↗

February 23, 2026

Via Chartmill

AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗

January 12, 2026

Via Chartmill

2 Under-the-Radar Stocks to Buy and Hold ↗

March 10, 2026

Via The Motley Fool

Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision ↗

March 09, 2026

Via The Motley Fool

Axsome Therapeutics to Participate in Upcoming Investor Conferences

February 25, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs

February 24, 2026

Via MarketMinute

Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms

February 24, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock ↗

February 23, 2026

Via Stocktwits

Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad

February 23, 2026

Via Finterra

Axsome (AXSM) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Via The Motley Fool

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 23, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036 ↗

February 22, 2026

Via The Motley Fool

Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 18, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

February 17, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Should You Buy Axsome Therapeutics Stock Before Feb. 23? ↗

February 05, 2026

Via The Motley Fool

1 High-Flying Stock With More Upside Ahead ↗

February 03, 2026

Via The Motley Fool

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

January 27, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership

January 26, 2026

Via MarketMinute

AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗

January 16, 2026

Via Stocktwits

Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

January 15, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

January 12, 2026

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗

January 08, 2026

Via MarketBeat

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?

Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?

Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?

The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market

What is the current price of Axsome Therapeutics, Inc. - Common Stock?

The current price of Axsome Therapeutics, Inc. - Common Stock is 168.74

When was Axsome Therapeutics, Inc. - Common Stock last traded?

The last trade of Axsome Therapeutics, Inc. - Common Stock was at 04/07/26 04:00 PM ET

What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?

The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 7.96B

How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?

Axsome Therapeutics, Inc. - Common Stock has 8B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.